Patents by Inventor Ruth E. Gimeno
Ruth E. Gimeno has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20200123260Abstract: The present invention relates to engineered heteromultimeric proteins, and more specifically, to methods for producing and purifying heterodimeric proteins, such as bispecific antibodies and. Methods for producing and purifying such engineered heterodimeric proteins and their use in diagnostics and therapeutics are also provided. The present invention also relates to a humanized antibody that specifically binds human TrkB and methods for producing and using the antibody to, inter alia, treat a hearing loss disorder.Type: ApplicationFiled: June 26, 2019Publication date: April 23, 2020Inventors: Eric M. Bennett, Nathan Higginson-Scott, Lioudmila Tchistiakova, Kimberly A. Marquette, Janet E. Paulsen, Ruth E. Gimeno
-
Patent number: 10392438Abstract: The present invention relates to engineered heteromultimeric proteins, and more specifically, to methods for producing and purifying heterodimeric proteins, such as bispecific antibodies and. Methods for producing and purifying such engineered heterodimeric proteins and their use in diagnostics and therapeutics are also provided. The present invention also relates to a humanized antibody that specifically binds human TrkB and methods for producing and using the antibody to, inter alia, treat a hearing loss disorder.Type: GrantFiled: May 13, 2015Date of Patent: August 27, 2019Assignee: PFIZER INC.Inventors: Eric M. Bennett, Nathan Higginson-Scott, Lioudmila Tchistiakova, Kimberly A. Marquette, Janet E. Paulsen, Ruth E. Gimeno
-
Publication number: 20180179285Abstract: The present invention relates to engineered heteromultimeric proteins, and more specifically, to methods for producing and purifying heterodimeric proteins, such as bispecific antibodies and. Methods for producing and purifying such engineered heterodimeric proteins and their use in diagnostics and therapeutics are also provided. The present invention also relates to a humanized antibody that specifically binds human TrkB and methods for producing and using the antibody to, inter alia, treat a hearing loss disorder.Type: ApplicationFiled: May 13, 2015Publication date: June 28, 2018Inventors: Eric M. Bennett, Nathan Higginson-Scott, Lioudmila Tchistiakova, Kimberly A. Marquette, Janet E. Paulsen, Ruth E. Gimeno
-
Patent number: 8334111Abstract: The present invention relates to compositions and methods for the diagnosis and treatment of obesity and related metabolic disorders. The invention provides isolated nucleic acids molecules, designated DGAT2 family member nucleic acid molecules, which encode diacylglycerol acyltransferase family members. The invention also provides recombinant expression vectors containing DGAT2 family member nucleic acid molecules, host cells into which the expression vectors have been introduced, and nonhuman transgenic animals in which a DGAT2 family member gene has been introduced or disrupted. The invention still further provides isolated DGAT2 family member proteins, fusion proteins, antigenic peptides and anti-DGAT2 family member antibodies. Methods of use of the provided DGAT2 family member compositions for screening, diagnostic and therapeutic methods in connection with obesity disorders are also disclosed.Type: GrantFiled: January 28, 2011Date of Patent: December 18, 2012Assignee: Millennium Pharmaceuticals, Inc.Inventors: Ruth E. Gimeno, Rosana Kapeller-Libermann, Zhidan Wu, Brian K. Hubbard
-
Publication number: 20120177661Abstract: The present invention relates to compositions and methods for the diagnosis and treatment of obesity and related metabolic disorders. The invention provides isolated nucleic acids molecules, designated DGAT2 family member nucleic acid molecules, which encode diacylglycerol acyltransferase family members. The invention also provides recombinant expression vectors containing DGAT2 family member nucleic acid molecules, host cells into which the expression vectors have been introduced, and nonhuman transgenic animals in which a DGAT2 family member gene has been introduced or disrupted. The invention still further provides isolated DGAT2 family member proteins, fusion proteins, antigenic peptides and anti-DGAT2 family member antibodies. Methods of use of the provided DGAT2 family member compositions for screening, diagnostic and therapeutic methods in connection with obesity disorders are also disclosed.Type: ApplicationFiled: March 20, 2012Publication date: July 12, 2012Inventors: Ruth E. Gimeno, Zhidan Wu, Rosana Kapeller-Libermann, Brian K. Hubbard
-
Publication number: 20120003233Abstract: The present invention relates to compositions and methods for the diagnosis and treatment of obesity and related metabolic disorders. The invention provides isolated nucleic acids molecules, designated DGAT2 family member nucleic acid molecules, which encode diacylglycerol acyltransferase family members. The invention also provides recombinant expression vectors containing DGAT2 family member nucleic acid molecules, host cells into which the expression vectors have been introduced, and nonhuman transgenic animals in which a DGAT2 family member gene has been introduced or disrupted. The invention still further provides isolated DGAT2 family member proteins, fusion proteins, antigenic peptides and anti-DGAT2 family member antibodies. Methods of use of the provided DGAT2 family member compositions for screening, diagnostic and therapeutic methods in connection with obesity disorders are also disclosed.Type: ApplicationFiled: January 28, 2011Publication date: January 5, 2012Applicant: Millennium Pharmaceuticals, Inc.Inventors: Ruth E. Gimeno, Zhidan Wu, Rosana Kapeller-Libermann, Brian K. Hubbard
-
Patent number: 7910346Abstract: The present invention relates to compositions and methods for the diagnosis and treatment of obesity and related metabolic disorders. The invention provides isolated nucleic acids molecules, designated DGAT2 family member nucleic acid molecules, which encode diacylglycerol acyltransferase family members. The invention also provides recombinant expression vectors containing DGAT2 family member nucleic acid molecules, host cells into which the expression vectors have been introduced, and nonhuman transgenic animals in which a DGAT2 family member gene has been introduced or disrupted. The invention still further provides isolated DGAT2 family member proteins, fusion proteins, antigenic peptides and anti-DGAT2 family member antibodies. Methods of use of the provided DGAT2 family member compositions for screening, diagnostic and therapeutic methods in connection with obesity disorders are also disclosed.Type: GrantFiled: February 17, 2009Date of Patent: March 22, 2011Assignee: Millennium Pharmaceuticals, Inc.Inventors: Ruth E. Gimeno, Rosana Kapeller-Libermann, Zhidan Wu, Brian K. Hubbard
-
Publication number: 20100035339Abstract: The present invention relates to compositions and methods for the diagnosis and treatment of obesity and related metabolic disorders. The invention provides isolated nucleic acids molecules, designated DGAT2 family member nucleic acid molecules, which encode diacylglycerol acyltransferase family members. The invention also provides recombinant expression vectors containing DGAT2 family member nucleic acid molecules, host cells into which the expression vectors have been introduced, and nonhuman transgenic animals in which a DGAT2 family member gene has been introduced or disrupted. The invention still further provides isolated DGAT2 family member proteins, fusion proteins, antigenic peptides and anti-DGAT2 family member antibodies. Methods of use of the provided DGAT2 family member compositions for screening, diagnostic and therapeutic methods in connection with obesity disorders are also disclosed.Type: ApplicationFiled: April 30, 2009Publication date: February 11, 2010Inventors: Ruth E. GIMENO, Zhidan WU, Rosana KAPELLER-LIBERMANN, Brian K. HUBBARD
-
Publication number: 20090269332Abstract: The present invention relates to compositions and methods for the diagnosis and treatment of obesity and related metabolic disorders. The invention provides isolated nucleic acids molecules, designated DGAT2 family member nucleic acid molecules, which encode diacylglycerol acyltransferase family members. The invention also provides recombinant expression vectors containing DGAT2 family member nucleic acid molecules, host cells into which the expression vectors have been introduced, and nonhuman transgenic animals in which a DGAT2 family member gene has been introduced or disrupted. The invention still further provides isolated DGAT2 family member proteins, fusion proteins, antigenic peptides and anti-DGAT2 family member antibodies. Methods of use of the provided DGAT2 family member compositions for screening, diagnostic and therapeutic methods in connection with obesity disorders are also disclosed.Type: ApplicationFiled: February 17, 2009Publication date: October 29, 2009Applicant: Millennium Pharmaceuticals, Inc.Inventors: Ruth E. Gimeno, Zhidan Wu, Rosana Kapeller-Libermann, Brian K. Hubbard
-
Patent number: 7527962Abstract: The present invention relates to compositions and methods for the diagnosis and treatment of obesity and related metabolic disorders. The invention provides isolated nucleic acids molecules, designated DGAT2 family member nucleic acid molecules, which encode diacylglycerol acyltransferase family members. The invention also provides recombinant expression vectors containing DGAT2 family member nucleic acid molecules, host cells into which the expression vectors have been introduced, and nonhuman transgenic animals in which a DGAT2 family member gene has been introduced or disrupted. The invention still further provides isolated DGAT2 family member proteins, fusion proteins, antigenic peptides and anti-DGAT2 family member antibodies. Methods of use of the provided DGAT2 family member compositions for screening, diagnostic and therapeutic methods in connection with obesity disorders are also disclosed.Type: GrantFiled: December 7, 2005Date of Patent: May 5, 2009Assignee: Millenium Pharmaceuticals, Inc.Inventors: Ruth E. Gimeno, Zhidan Wu, Rosana Kapeller-Libermann, Brian K. Hubbard
-
Publication number: 20080241129Abstract: Disclosed herein are methods of using Ccdc80, Ccdc80 mimics, or Ccdc80 agonists or antagonists in the treatment of bone disorders.Type: ApplicationFiled: February 14, 2008Publication date: October 2, 2008Applicant: WyethInventors: Ruth E. Gimeno, Frederic Tremblay, Shoichi Fukayama
-
Patent number: 7033772Abstract: A family of fatty acid transport proteins (FATPs) mediate transport of long chain fatty acids (LCFAs) across cell membranes into cells. These proteins exhibit different expression patterns among the organs of mammals. Nucleic acids encoding FATPs of this family, vectors comprising these nucleic acids, as well as the production of FATP proteins in host cells are described. Also described are methods to test FATPs for fatty acid transport function, and methods to identify inhibitors or enhancers of transport function. The altering of LCFA uptake by administering to the mammal an inhibitor or enhancer of FATP transport function of a FATP in the small intestine can decrease or increase calories available as fats, and can decrease or increase circulating fatty acids. The organ specificity of FATP distribution can be exploited in methods to direct drugs, diagnostic indicators and so forth to an organ such as the heart.Type: GrantFiled: September 23, 1999Date of Patent: April 25, 2006Assignees: Millennium Pharmaceuticals, Inc., Whitehead Institute for Biomedical ResearchInventors: Andreas Stahl, David J. Hirsch, Harvey F. Lodish, Ruth E. Gimeno, Louis A. Tartaglia
-
Publication number: 20030232363Abstract: A family of fatty acid transport proteins (FATPs) mediate transport of long chain fatty acids (LCFAs) across cell membranes into cells. These proteins exhibit different expression patterns among the organs of mammals. Nucleic acids encoding FATPs of this family, vectors comprising these nucleic acids, as well as the production of FATP proteins in host cells are described. Also described are methods to test FATPs for fatty acid transport function, and methods to identify inhibitors or enhancers of transport function. The altering of LCFA uptake by administering to the mammal an inhibitor or enhancer of FATP transport function of a FATP in the small intestine can decrease or increase calories available as fats, and can decrease or increase circulating fatty acids. The organ specificity of FATP distribution can be exploited in methods to direct drugs, diagnostic indicators and so forth to an organ such as the heart.Type: ApplicationFiled: April 1, 2003Publication date: December 18, 2003Inventors: Andreas Stahl, David J. Hirsch, Harvey F. Lodish, Ruth E. Gimeno, Louis A. Tartaglia
-
Publication number: 20030170691Abstract: The present invention relates to compositions and methods for the diagnosis and treatment of obesity and related metabolic disorders. The invention provides isolated nucleic acids molecules, designated DGAT2 family member nucleic acid molecules, which encode diacylglycerol acyltransferase family members. The invention also provides recombinant expression vectors containing DGAT2 family member nucleic acid molecules, host cells into which the expression vectors have been introduced, and nonhuman transgenic animals in which a DGAT2 family member gene has been introduced or disrupted. The invention still further provides isolated DGAT2 family member proteins, fusion proteins, antigenic peptides and anti-DGAT2 family member antibodies. Methods of use of the provided DGAT2 family member compositions for screening, diagnostic and therapeutic methods in connection with obesity disorders are also disclosed.Type: ApplicationFiled: December 19, 2002Publication date: September 11, 2003Applicant: Millennium Pharmaceuticals, Inc.Inventors: Ruth E. Gimeno, Zhidan Wu, Rosana Kapeller-Libermann, Brian K. Hubbard
-
Publication number: 20030165430Abstract: The present invention provides a transgenic Fatty Acid Transport One (FATP1), non-human knockout mammal, e.g., mammal, useful for elucidating the function of FATP in intact animals whose genomes comprise a wild-type FATP gene. Further aspects of the invention provide a method for the identification of agents, e.g., therapeutic agents, that inhibit FATP1 activity, and methods of treating diseases or conditions associated with FATP1 function, e.g., insulin resistance, non-insulin dependent diabetes mellitus, and cellular triglyceride accumulation.Type: ApplicationFiled: December 12, 2002Publication date: September 4, 2003Applicant: Whitehead Institute for Biomedical ResearchInventors: Gerald I. Shulman, Jason K. Kim, Ruth E. Gimeno, Harvey F. Lodish, David J. Hirsch, Andreas Stahl
-
Publication number: 20030113889Abstract: The invention provides isolated nucleic acids molecules, designated FARS1 nucleic acid molecules, which encode novel secreted proteins. The invention also provides antisense nucleic acid molecules, recombinant expression vectors containing FARS1 nucleic acid molecules, host cells into which the expression vectors have been introduced, and nonhuman transgenic animals in which a FARS1 gene has been introduced or disrupted. The invention still further provides isolated FARS1 proteins, fusion proteins, antigenic peptides and anti-FARS1 antibodies. Diagnostic and therapeutic methods utilizing compositions of the invention are also provided.Type: ApplicationFiled: May 21, 2002Publication date: June 19, 2003Applicant: Millennium Pharmaceuticals, Inc.Inventors: Ruth E. Gimeno, Mehran M. Khodadoust
-
Patent number: 6348321Abstract: A family of fatty acid transport proteins (FATPS) mediate transport of long chain fatty acids (LCFAs) across cell membranes into cells. These proteins exhibit different expression patterns among the organs of mammals. Nucleic acids encoding FATPs of this family, vectors comprising these nucleic acids, as well as the production of FATP proteins in host cells are described. Also described are methods to test FATPs for fatty acid transport function, and methods to identify inhibitors or enhancers of transport function. The altering of LCFA uptake by administering to the mammal an inhibitor or enhancer of FATP transport function of a FATP in the small intestine can decrease or increase calories available as fats, and can decrease or increase circulating fatty acids. The organ specificity of FATP distribution can be exploited in methods to direct drugs, diagnostic indicators and so forth to an organ such as the heart.Type: GrantFiled: January 14, 1999Date of Patent: February 19, 2002Assignees: Whitehead Institute for Biomedical Research, Millennium Pharaceuticals, Inc.Inventors: Andreas Stahl, David J. Hirsch, Harvey F. Lodish, Ruth E. Gimeno, Louis A. Tartaglia
-
Patent number: 6300096Abstract: A family of fatty acid transport proteins (FATPs) mediate transport of long chain fatty acids (LCFAs) across cell membranes into cells. These proteins exhibit different expression patterns among the organs of mammals. Nucleic acids encoding FATPs of this family, vectors comprising these nucleic acids, as well as the production of FATP proteins in host cells are described. Also described are methods to test FATPs for fatty acid transport function, and methods to identify inhibitors or enhancers of transport function. The altering of LCFA uptake by administering to the mammal an inhibitor or enhancer of FATP transport function of a FATP in the small intestine can decrease or increase calories available as fats, and can decrease or increase circulating fatty acids. The organ specificity of FATP distribution can be exploited in methods to direct drugs, diagnostic indicators and so forth to an organ such as the heart.Type: GrantFiled: January 14, 1999Date of Patent: October 9, 2001Assignees: Whitehead Institute for Biomedical Research, Millennium Pharmaceuticals, Inc.Inventors: Andreas Stahl, David J. Hirsch, Harvey F. Lodish, Ruth E. Gimeno, Louis A. Tartaglia
-
Patent number: 6288213Abstract: A family of fatty acid transport proteins (FATPs) mediate transport of long chain fatty acids (LCFAs) across cell membranes into cells. These proteins exhibit different expression patterns among the organs of mammals. Nucleic acids encoding FATPs of this family, vectors comprising these nucleic acids, as well as the production of FATP proteins in host cells are described. Also described are methods to test FATPs for fatty acid transport function, and methods to identify inhibitors or enhancers of transport function. The altering of LCFA uptake by administering to the mammal an inhibitor or enhancer of FATP transport function of a FATP in the small intestine can decrease or increase calories available as fats, and can decrease or increase circulating fatty acids. The organ specificity of FATP distribution can be exploited in methods to direct drugs, diagnostic indicators and so forth to an organ such as the heart.Type: GrantFiled: January 14, 1999Date of Patent: September 11, 2001Assignee: Whitehead Institute for Biochemical ResearchInventors: Andreas Stahl, David J. Hirsch, Harvey F. Lodish, Ruth E. Gimeno, Louis A. Tartaglia